Media headlines about Zafgen (NASDAQ:ZFGN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Zafgen earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.2595858694917 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Zafgen (NASDAQ:ZFGN) opened at $8.15 on Tuesday. The company has a market capitalization of $217.72, a price-to-earnings ratio of -4.50 and a beta of -0.51. Zafgen has a twelve month low of $3.21 and a twelve month high of $8.95.
A number of analysts have recently commented on ZFGN shares. ValuEngine upgraded Zafgen from a “strong sell” rating to a “sell” rating in a report on Monday, October 16th. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Saturday, November 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. Zafgen has an average rating of “Hold” and a consensus price target of $6.63.
TRADEMARK VIOLATION WARNING: “Zafgen (ZFGN) Receiving Somewhat Favorable News Coverage, Study Shows” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/02/13/zafgen-zfgn-receiving-somewhat-favorable-news-coverage-study-shows.html.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.